Jason Gilleran, MD
Urology · Royal Oak, MINPI 1790734721
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 21.7%. Reporting peaked in 2023 at $6,155 and has fallen 80.9% since, to $1,178 in 2025.
Across 326 payments — averaging $42.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- Axonics, Inc.$3K
- Medtronic$2K
- Astellas Pharma US Inc$948
- Procept Biorobotics Corporation$902
- Rochester Medical Corporation$668
- plus $3K from 37 others
Across 26 payments — averaging $544.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axonics, Inc.$14K
What the payments were for
- Speaking & faculty fees$3,03622%
- Travel & lodging$3,28724%
- Food & beverage$7,34953%
- Education$3072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$3,036
- Axonics$1,979
- INTERSTIM$1,575
- Bulkamid$1,097
- AquaBeam Robotic System$625
- ALTIS$165
- GENERAL FEMALE SUI$135
- Solyx SIS System$113
How this compares
$13,979 in reported general payments places this provider in the 80th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 259 | $209,454 |
| GemtesaVibegron | 81 | $64,581 |
| Mirabegron ErMirabegron | 64 | $42,365 |
| Methenamine Hippurate | 155 | $11,725 |
| Estradiol | 190 | $11,580 |
| Tamsulosin Hcl | 352 | $6,532 |
| Cyclosporine | 14 | $5,792 |
| Trospium Chloride ErTrospium Chloride | 26 | $4,978 |
| Potassium Citrate ErPotassium Citrate | 42 | $4,565 |
| Dutasteride | 113 | $4,361 |
| Trospium Chloride | 77 | $3,946 |
| Finasteride | 98 | $1,802 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $1,640 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 21 | $801 |
| NitrofurantoinNitrofurantoin Macrocrystal | 32 | $764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $948 | $209,454259 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $218 | $64,58181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 urology providers in Michigan.
Other urology in Royal Oak
- Richard BennettRoyal Oak$361K
- Kenneth PetersRoyal Oak$28K
- Adam GadzinskiRoyal Oak$22K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Ryan NelsonUtica$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.